AstraZeneca Snubs Pfizer's Sweetened $106B Offer
AstraZeneca PLC snubbed Pfizer's sweetened cash-and-stock merger offer Friday, saying the £63 billion ($106 billion) price tag is "inadequate" and fails to appreciate the U.K. drugmaker's pipeline of pharmaceuticals under development....To view the full article, register now.
Already a subscriber? Click here to view full article